Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Umirolimus Stories

2013-05-26 08:20:18

SINGAPORE, May 26, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced the completion of its acquisition of substantially all assets of Spectrum Dynamics, a leader in advanced functional assessment technologies, including those used to evaluate patients for cardiac interventions. The deal consideration is approximately...

2013-05-16 08:27:27

Interventional Cardiology Pioneer Aims to Offer Improved Detection of Cardiovascular Disease SINGAPORE, May 16, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, announced on May 13, 2013 that it has entered into an agreement to acquire substantially all assets of Spectrum Dynamics, a leader in advanced functional assessment...

2013-02-07 12:27:06

SINGAPORE, Feb. 7, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced financial results for its third fiscal quarter ("Q3 FY13") and nine months ended 31 December 2012 ("FY13 nine-month period"). Financial Performance and Recent Highlights: In January, Biosensors received CE Mark approval for its polymer-free...

2013-01-28 20:21:55

SINGAPORE, Jan. 28, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced CE Mark approval for its polymer-free drug-coated stent (DCS), BioFreedom(TM). BioFreedom represents the latest development in Biosensors' stent technology, featuring a micro-structured abluminal surface which permits the controlled release of Biolimus...

2012-11-07 08:28:52

SINGAPORE, Nov. 7, 2012 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG:SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced financial results for the second quarter of fiscal year 2013 (Q2 FY13) and the fiscal six months ended 30 September 2012 (H1 FY13). Q2 FY13 and Recent Highlights: Total revenue of US$79.8 million, representing 28% year-on-year growth Interventional...